Study details
Enrolling now
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Robert Nickel
NCT IDNCT03587272ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 13 years
Ages
2–25
Locations
5 sites in DC, IL, NC +2
About this study
This trial is testing a new way to transplant bone marrow from an identical sibling donor into children with sickle cell disease. The goal is to reduce the side effects of this treatment while still achieving a high success rate.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Alemtuzumab, low dose total body irradiation, Sirolimus
PhasePhase 2
DrugAlemtuzumab
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
alemtuzumab, sirolimus
Drug routes
injection (Injection), injection, intravenous
Endpoints
Secondary: PedsQL 4.0 Measurement model for the Pediatric Quality of Life Inventory